Try our Advanced Search for more refined results
Health
-
March 30, 2026
Minn. Panel Says Med Mal Experts Wrongly Axed, Revives Suit
A Minneapolis hospital system must face claims that an obstetrician violated her standard of care during delivery causing permanent impairment to a child's right arm and hand, a Minnesota appeals court ruled on Monday, saying the trial court improperly disqualified the parents' expert witnesses.
-
March 30, 2026
5th Circ. Seems Open To Reviving Eyemart Class Action
A Fifth Circuit panel seemed open to reviving a class action accusing glasses retailer Eyemart Express LLC of selling sensitive personal health information to social media giant Meta, asking Monday why dismissal was appropriate given the complexity of the case.
-
March 30, 2026
Don't Set Special IP Rules For 'Skinny Labels,' Justices Told
Drugmakers, industry groups, hospitals and scholars have urged the U.S. Supreme Court to uphold a decision letting a patent suit proceed over a generic drug using a so-called skinny label, saying the generics company is seeking unwarranted special protections that would upend patent law.
-
March 30, 2026
Fla. Hospital System Patients Get Class Cert. Denied
A Florida federal court refused to certify a class of consumers in a case accusing Health First Inc. of locking in patients and blocking competition from rival hospital systems, after finding a number of issues, including potential differences between proposed class members.
-
March 30, 2026
Foreseeability 'Tricky' For Yale Doc's 1981 Act, Court Told
Yale New Haven Health Services Corp. on Monday asked a Connecticut state judge to strike seven of 10 counts from a lawsuit accusing a doctor of using his own sperm to impregnate a fertility patient, saying it was not foreseeable in 1981 that technology might some day reveal the doctor's actions.
-
March 30, 2026
Product Liability Q1 Regulatory Roundup
In the first three months of 2026, executive orders and other regulatory actions by the Trump administration have taken on products with "Made in America" labeling, called for the increased manufacture of the herbicide ingredient glyphosate, and addressed what e-cigarette flavors could receive the U.S. Food and Drug Administration's approval, among others.
-
March 30, 2026
FCA Qui Tams Are Unconstitutional, Eli Lilly Tells Justices
The False Claims Act's whistleblower provisions are unconstitutional, drugmaker Eli Lilly has told the U.S. Supreme Court, asking it to overturn a Seventh Circuit decision upholding a $183 million trial win for a whistleblower who claimed the drug company hid how much it charged for Medicaid-covered drugs.
-
March 30, 2026
5th Circ. Calls Pharmacy GLP-1 Args 'Tough Pills To Swallow'
A Fifth Circuit panel pushed multiple compounding pharmacies to explain why they should get to compound lucrative drugs used for weight loss, including Ozempic, saying Monday that its options if it sides with the pharmacies are "tough pills to swallow."
-
March 30, 2026
Eye Doctor Appeals Microcaptive Tax Payments At 5th Circ.
An eye doctor and his wife asked the Fifth Circuit to overturn a U.S. Tax Court decision from last year that affirmed Internal Revenue Service penalties and payments associated with their ophthalmology practice's microcaptive insurance arrangements.
-
March 30, 2026
Steward Health Creditor Trustee Sues Aetna For $6.4M
The leader of a creditor litigation trust in Steward Health Care's bankruptcy case has launched an adversary proceeding in Texas bankruptcy court against Aetna Health, saying the insurer has refused to pay $6.36 million owed to hospitals formerly owned by Steward.
-
March 30, 2026
FTC Says Anesthesia Group Cheered While Raising Prices
The Federal Trade Commission pushed back against a bid from U.S. Anesthesia Partners to avoid facing trial on claims that it monopolized the market through a rollup strategy, saying the company celebrated its ability to dramatically increase prices.
-
March 30, 2026
Cleary-Led Blackstone Wraps Record $6.3B Life Sci Fund
Private equity giant Blackstone, led by Cleary Gottlieb Steen & Hamilton LLP, revealed Monday that it wrapped its sixth life sciences fund after securing $6.3 billion of capital commitments, marking what the firm says is the largest private life sciences fund ever raised.
-
March 30, 2026
Eli Lilly's $2.75B Pact Is Latest In AI Drug Discovery Push
Eli Lilly and Co. has agreed to a partnership with artificial intelligence-driven drug discovery company Insilico that could be worth up to $2.75 billion, amid an expanding category of collaboration fueled by pharmaceutical giants seeking accelerated paths to new treatments.
-
March 30, 2026
TriZetto's $70M Trade Secret Verdict Upheld, Total Award Cut
A New York federal judge has upheld a $70 million compensatory damages verdict for the TriZetto Group in a long-running trade secret fight against Syntel Inc., while also cutting punitive damages to about $140 million and awarding TriZetto more than $12 million in attorney fees.
-
March 30, 2026
J&J Unit Wants Forensic Exam Of Ex-Director's Devices
A Johnson & Johnson subsidiary urged a New Jersey federal court to order a former associate director to submit to a court-supervised forensic inspection of any device or account in which she could have stored confidential information it claims she downloaded in order to start her own competing company.
-
March 30, 2026
Justices Pass On FCA Suit Alleging Quest Diagnostics Fraud
The U.S. Supreme Court rejected on Monday a former Quest Diagnostics Inc. compliance officer's bid for review of the dismissal of a long-running False Claims Act suit against the medical testing company.
-
March 30, 2026
Justices Reject TM Appeal Tied To 'Use In Commerce'
The U.S. Supreme Court on Monday declined to take up an appeal challenging a Ninth Circuit ruling that upheld a multimillion-dollar default judgment based largely on statements defendants made in trademark applications.
-
March 27, 2026
Elizabeth Holmes Gets 11-Year Prison Sentence Cut By A Year
A California federal judge has shaved off a year from convicted ex-Theranos CEO Elizabeth Holmes' 11-year-and-three-month prison sentence for securities fraud due to recent sentencing guideline amendments, reducing her time behind bars by one year, instead of the two years she requested, amid objections by prosecutors.
-
March 27, 2026
Eye Clinic's Hurricane Damage Suit Sent To Territorial Court
A federal judge in the U.S. Virgin Islands has sent back to territorial court an ophthalmology clinic's lawsuit seeking punitive damages from its insurers that allegedly underpaid claims resulting from Hurricane Maria, which swept through the Caribbean in 2017 and caused about $1 million of lost income and damage to its property.
-
March 27, 2026
Eli Lilly Keeps Most Of Weight Loss Drug Copy Suit Alive
A California federal judge has refused to throw out a lawsuit accusing a pair of telehealth companies of making copies of Eli Lilly's obesity and type 2 diabetes drugs but agreed to trim the case.
-
March 27, 2026
NC Biz Court Bulletin: Judge Exits, Duke Ducks Climate Suit
The North Carolina Business Court saw an unexpected shakeup with one judge's retirement, rendered a pivotal decision in a first-of-its-kind climate change case against Duke Energy and oversaw a trial between the feuding owners of a commercial bed skirt company.
-
March 27, 2026
5th Circ. Won't Revive Ex-Health IT Co. Worker's Bias Suit
The Fifth Circuit upheld a healthcare information technology provider's win over a Black former manager's lawsuit claiming she was fired for complaining that a white male colleague was treated better, saying she couldn't overcome the company's rationale for letting her go.
-
March 27, 2026
Hospital System Beats Most Of REIT's $50M Floodwall Suit
A New York federal judge on March 27 mostly tossed a real estate investment trust's $50 million suit against the New York City Health and Hospitals Corp. and the NYC Economic Development Corp. over the design of a proposed floodwall for a downtown Manhattan life sciences campus project.
-
March 27, 2026
Skincare Co. Says ITC Ruling Backs Ending PTAB Challenge
Skin products company Hydrafacial has argued U.S. Patent and Trademark Office Director John Squires should turn down a rehearing request from rival Sinclair Pharma over Squires' order de-instituting a challenge to Hydrafacial's patent, saying a U.S. International Trade Commission decision upholding the same patent supports the director's move.
-
March 27, 2026
Sens. Push Bill To Equip VA For Psychedelic Therapies
A bipartisan group of U.S. senators has introduced legislation to broaden veterans' access to emerging therapies, including psychedelic-assisted treatments, that may be effective in addressing post-traumatic stress disorder and other mental health issues.
Expert Analysis
-
Series
Playing Piano Makes Me A Better Lawyer
Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.
-
11th Circ. May Bring Tectonic Shift To FCA Qui Tam Actions
The Eleventh Circuit's upcoming decision in Zafirov v. Florida Medical Associates, assessing whether the False Claims Act permits ordinary citizens to stand as officers of the federal government, could significantly limit private relators' ability to bring FCA actions, say attorneys at Saul Ewing.
-
AI-Generated Doc Ruling Guides Attys On Privilege Risks
A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.
-
To Survive FCA Actions, Small Cos. Must Take Offensive Steps
A fumbled response to False Claims Act allegations can doom lower-middle-market businesses, and with FCA enforcement hitting record levels for two years, smaller companies must have offensive strategies ready that focus their limited resources on defeating civil qui tam and federal criminal actions, says Derrelle Janey at Olshan Frome.
-
The Law Firm Merger Diaries: Leadership Strategy After Day 1
For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.
-
How US Liability Law Is Becoming The Primary Regulator Of AI
Comprehensive federal AI regulation remains fragmented and uncertain — but U.S. courts, applying long-standing doctrines of liability and responsibility, are actively shaping how AI systems are designed, deployed and governed, and companies are aligning their AI practices because courts may hold them accountable if they do not, says Alexander Lima at Wesco International.
-
Record FCA Recoveries Signal Intensified Healthcare Focus
In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.
-
Fed. Circ. In Jan.: On The Validity Of Expert Testimony
The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.
-
Methods For Challenging State Civil Investigative Demands
Ongoing challenges to enforcement actions underscore the uphill battle businesses face in arguing that a state investigation is prohibited by federal law, but when properly deployed, these arguments present a viable strategy to resist civil investigative demands issued by state attorneys general, say attorneys at Troutman Pepper.
-
Calif.'s Civility Push Shows Why Professionalism Is Vital
The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.
-
A Potential Shift In FDA's Approach To Drug Trial Design
Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.
-
Opinion
SNAP Rule Confusion Risks A Compliance Crisis
Recent Supplemental Nutrition Assistance Program food restriction waivers pose a compliance crisis for legal practitioners advising food retailers, amid higher costs and lack of a coherent national standard, says Tyson-Lord Gray at Yeshiva University’s Benjamin N. Cardozo School of Law.
-
Series
Trivia Competition Makes Me A Better Lawyer
Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.
-
What FDA Guidance Means For Future Of Health Software
Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.
-
Opinion
Federal Preemption In AI And Robotics Is Essential
Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.